Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 17Neoplasm Metastasis 6Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Colorectal Neoplasms 2Solid Cancer 1Salivary Gland Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neoplasm, Residual 1HER2-positive Breast Cancer 1HER2-mutant Non-Small Cell Lung Cancer 1HER2-Positive Primary Breast Cancer 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Breast Diseases 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

trastuzumab deruxtecan 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × HER2-Positive Primary Breast Cancer × trastuzumab deruxtecan × Clear all
NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡